Ibrutinib (Imbruvica)
Drug timelines are a Plus or Pro feature.
7 regulatory and trial events tracked for Ibrutinib (Imbruvica), covering 2015-04-16 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) [Phase 3]